• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    1493961 Basic ethers ELI LILLY & CO 9 Jan 1975 [10 Jan 1974] 898/75 Heading C2C Compounds of the general formula (each R 1 and R 2 independently H or Me; R 3,4 = halogen, CF 3 , C 2-4 alkyl, C 1-3 alkoxy, C 3-4 alkenyl; m, n = 0-2, but not both 0 when both R 1 = Me and both R 2 =H) and their acid addition salts are prepared by (a) reaction of PRCHXCHR 2 CHR 2 NMe 2 (X=halogen) with the appropriate phenol, optionally followed by conversion to the secondary amine by treatment with cyanogen bromide followed by hydrolysis or to the primary amine by oxidation of the secondary amine with neutral permanganate, or (b) reaction of the corresponding #-aroxy-#- phenalkyl chloride with ammonia, methylamine or dimethylamine, or with sodium azide followed by reduction, optionally followed in each case by salt formation and/or isomer separation. The preparation of starting materials for processes (a) and (b) by standard methods is described. The above compounds are psychotropic agents, and may be administered in the form of pharmaceutical preparations containing them in association with a carrier.
    公开号:SU1005655A3
    申请号:SU752101119
    申请日:1975-01-09
    公开日:1983-03-15
    发明作者:Барнет Моллой Бройан；Курт Шмигель Клаус
    申请人:Эли Лилли Энд Компани (Фирма)；
    IPC主号:
    专利说明:

    The invention relates to a method for producing new derivatives of 3 - aryloxy-3 ~ phenylpropylamine of the general formula
    where R ^ and Rj are a hydrogen atom or methyl;
    R 3 is a hydrogen atom, a halogen atom, trifluoromethyl, -alkyl,
    -alkoxygroup or C ^ _ ^ - -alkenyl, provided that it is not a hydrogen atom, when both are simultaneously hydrogen atoms or methyl, or their salts with a psychotropic effect.
    It is known that some phenyl-substituted alkylamines have a pronounced pharmacological effect.
    In particular, tertiary 2-phenoxy-2-phenylalkylamines exhibit analeptic, antihistamine and anticholinergic activity of £ 1}.
    A known method for producing mixed alkylaryl ethers by reacting the corresponding phenols and haloalkyls by heating in an organic solvent in the presence of inorganic bases £ 2j.
    The aim of the invention is to expand the means of influence on a living organism.
    This goal is achieved by the fact that according to the method of obtaining 3 "
    -aryloxy-3 _ phenyl ~ propylamines of the general formula 1 or their salts N, N-dimethyl-H- (3 “phenyl ~ 3-chloropropyl) -amine of the general formula
    1005655 4
    Cl — sich-ch-h (sl 5 ) g where Ri has the above meaning, is treated with phenol of the general formula
    where 8, ¾ has the above meaning and, if necessary, demethylation of the obtained compound is carried out and the target product is isolated in free form or in the form of a salt.
    Example. Ν-Μετππ-Ν- (3 ~ (p-jo-trifluoromethylphenoxy) -3 _ phenyl-propyl ^ -amine and N, N-dimethyl-H- [3 _ ptrifluoromethylphenoxy) ~ 3 ~ Phenyl] propylamine.
    600 g of β-dimethylamino-and propiophenone hydrochloride are converted to the free base by treatment with a 1.5 N sodium hydroxide solution. The liberated free base is extracted with ether, the ether layer is separated and dried, 30 after which the ether is removed in vacuo. The remaining oil containing p-dimethylaminopropiophenone is dissolved in 2 L of tetrahydrofuran and the resulting solution is added dropwise with stirring to a solution of 4 mol of diborane. 35 in 4 L tetra of hydrofuran. The reaction mixture was stirred overnight at room temperature, an additional 1 mol of diborane in tetrahydrofuran was added, and 40 was stirred overnight at room temperature. Then add 2 l of an aqueous solution of hydrochloric acid to decompose the excess of diboran present. Tetra hydrofuran is distilled off 1 , salt 45 acidic solution is extracted twice
    1 liter servings of benzene. The remaining acidic solution is then alkalinized with an excess of 5 N aqueous sodium hydroxide solution. The alkaline solution 50 is extracted three times with 2 liter portions of benzene. The benzene extracts are separated, combined, washed with a saturated aqueous solution of sodium chloride and then dried. 55 After evaporation of the solvent in vacuo gave 442 g of N, CM-dimethyl-TS- (3 "-phenyl-3 _ hydroxypropyl) -amine.
    A solution containing 442 γΗ, Ν-dimethyl-N- (3 “phenyl-3” hydroxypropyl) amine in 5 L of chloroform is saturated with dry gaseous hydrogen chloride - . house, after which 400 ml of thionyl chloride are added to it at a rate sufficient to maintain the boiling of the reaction mixture. The solution was refluxed for an additional 5 hours. After evaporation of chloroform and other volatile components in vacuo, N, I-dimethyl-N- (3 _ phenyl-3 _ chloropropyl) amine hydrochloride was obtained, which was filtered off and washed with twice × 1500 ml of acetone. 500 g of the title compound are obtained with mp. 181-183 ° C (with decomposition). Additionally, 30 g of the title compound are obtained from washing acetone after distillation of the solvent and crystallization of the residue. The structure of the indicated compound was established by NMR and titration.
    A solution of 50 g of p-trifluoromethylphenol, 12 g of sodium hydroxide and 400 ml of methanol is placed in a 1 liter round bottom flask equipped with a magnetic stirrer, reflux condenser, calcium chloride tube. The reaction mixture is stirred until sodium hydroxide dissolves. 'Then 29.8 g of N, C-dimethyl-C- (3 ~ phenyl ~ 3 _ chloropropyl) -amine hydrochloride are added. The resulting reaction mixture was refluxed for about 5 days and then cooled. The methanol was distilled off, the residue was treated with a mixture of ether and 5 N aqueous sodium hydroxide. The ether layer is separated, washed twice with 5N aqueous sodium hydroxide solution, thrice with water and then dried. After distillation of the ether under reduced pressure, N, M-dimethyl-N- £ 3- (p-trifluoromethylphenoxy-3 “phenylpropyl] amine is obtained.
    The free base is then converted to the corresponding oxalate salt by mixing a solution of 32 g of the above amine in atyl acetate and a solution of 9 g of oxalic acid in ethyl acetate. After distillation of ethyl acetate under elevated pressure, N, N-dimethyl-H-£ 3 “(p-trifluoromethyl-phenoxy) -3-phenyl-propyl] -ammonium oxalate is obtained having a mp of 117119 C (decomposed) after recrystallization from ethyl acetate.
    Calculated D: C 58.11, H 3.36; N, 3.39; F 13.79.
    Found D: C 58.19 *, H 3.49 ',
    N, 3.59; F 13.85.
    A solution containing 8.1 g of cyanide bromide in 500 ml of benzene and 50 ml of toluene is placed in a 1 liter three-necked, round-bottom flask equipped with a thermometer, dropping funnel, calcium chloride tube and nitrogen inlet tube. The solution was cooled to 5 ° C with stirring, then nitrogen was passed through the solution, and a solution of 12.146 g of N, I-dimethyl-H- £ 3 “p-trifluoromethylphenoxy) -3-phenylpropyl] amine in 40 ml of benzene was added dropwise. The temperature of the reaction mixture was gradually brought to room temperature and the reaction mixture was stirred at room temperature overnight in a nitrogen atmosphere. Then, 100 ml of benzene was added to the reaction mixture, washed twice with water, once with 2 N sulfuric acid solution and then with water until the pH was neutral. The organic layer was dried and evaporated under reduced pressure. Obtain 9.5 g of an oily residue containing N-methyl-N-cyano-M- [3 _ (p-trifluoromethylphenoxy) -3 ~ phenylpropyl] -amine.
    A solution of 100 g of potassium hydroxide in 85 ml of water and 400 ml of ethylene glycol and 9.5 g of m-methyl-H _ cyano-n- £ 3 (p-trifluoromethylphenoxy) -3-phenylpropylj-amine in a 1 liter three-necked flask equipped with a magnetic stirrer and reflux, heated at boiling point (about 130 ° C) for 20 hours and then cooled. Add 500 ml of water. Reactionary. the mixture is extracted with three portions of 500 ml ether. The ether extracts are combined, washed with water and treated with 2 N aqueous hydrochloric acid. The acidic aqueous layer is separated. The remaining ether layer was extracted three times with water and once with a saturated aqueous solution of sodium chloride. The aqueous layers were combined, basified with 5 N aqueous sodium hydroxide and the precipitated N-methyl-N- £ 3 (p-trifluoromethylphenoxy) -3 ~ phenylpropyl-amine was separated. The amine is extracted three times with ether, the ether extracts are combined, washed with a saturated aqueous solution of sodium chloride and then dried. After evaporation of the ether under reduced pressure, 6.3 g of Ν-ΜβτΗΠ-Ν- £ 3 _ (η-τρΗφτορ10. 15 $ 5) are obtained.
    Η 5.05;
    5.30;
    of respectively
    1005855 6 methylphenoxy) -Z-phenylpropyl / amine. The target product in the form of a free base is converted into the corresponding oxalate salt by the method described above. N-methyl “Ν- [3 (p-trifluoromethylphenoxy) -3 ~ phenylpropyl / ammonium oxalate is obtained, having a melting point of 179182 ° C (with decomposition) after recrystallization from a mixture of ethyl acetate - methanol.
    Calculated D: C 57.14; 3.51 *, F 14.27 Found D: C 57.431 H 3.79; F, 14.24.
    The following N f N-dimethyl- or N-methyl-N- £ 3 aryloxy-3 ~ phenylpropyl / amines are prepared analogously to the described starting compounds. ''
    Maleate N · S-dimethyl-S-O (o-chlorophenoxy) -3 _ Phenylpropyl] -ammonium, which melts at 88-90 ° C after recrystallization from a mixture of ethyl acetate - cyclohexane.
    Calculated D: C, 62.14; H, 5.96; N, 3.45; C1 8.73. . .
    Found D: C, 61.94 *, H, 5.651; N, 3.68; CE 8.92.
    Ν, Ν-dimethyl-N- £ 3- (o-trifluoromethylphenoxy) -3-phenylpropyl / ammonium p-toluenesulfonate, which melts at 134-136 ° C after recrystallization from ethyl acetate.
    Calculated D: C 60.59. ', H 5.70', 2.8z; f and, 50; s 6.47.
    Found D: C, 60.36; H 5.52;
    3.12; F And, 8o; S 6.66.
    Ν-Μβτππ-Ν- [3 - phenyl ~ 3 (m-chlorophenoxy) -propyl] -ammonium oxalate. Mp 177-179 ° C.
    Calculated D: C 59.10, 'And 5.511 N 3.831 C2 9.69.
    Found D: C 58.891 H 5.451
    N, 4.071 Ct; 9.24;
    Oxalate Nj N-dimethyl-N- (3 “(m- methoxyphenoxy) '- 3-phenylpropyl / ammonium. Mp 125-128 ° C.
    Calculated D: C 63.99 ', H 6.91;
    N, 3.73.
    Found D: C 63.931 H 6.901
    N, 3.59.
    N N-dimethyl-N- £ 3 “(o-allylphenoxy) - / phenyl-propyl] -ammonium oxalate. Mp 159-1b1 ° C.
    Calculated D: C 68.551 H 7, V;
    N, 3.63.
    Found D: C 68.671 H 7.151
    N, 3.83.
    Ί 1,005,655
    N, M-dimethyl-N- [3 “(p-chlorophenoxy) -3-phenylpropyl] ~ ammonium oxalate. Mp 139-1 ^ 1 ^ 0 /
    Calculated, : C 60.08) H 5.84;
    N 3.69) C 9.33 Found,%: С 60, ЗМ Н 5.95) 'N 3.88,' С g 9.6-1.
    Maleate N, H-dimethyl-I - £ 3- (o-methoxyphenoxy) -3-phenylpropyl] -ammonium. Mp 98-103 ° C.
    Calculated, : С 6ζ, 32 ι , Н 6.78)
    N 3 / <9.
    Found, : C 65.83) H 6.52)
    N, 3.63.
    Maleate Ν, M-dimethyl-M- £ 3 (p-methoxyphenoxy) -3 ~ phenylpropyl] -ammonium 101-104 R C.
    Calculated, : C 65.82 *, H 7.8)
    N ZL9.
    Found D: C, 65.96; H 6.50 ',
    N, 3.68.
    Maleate No. methyl-M- [3- (p-fluorophenoxy) -3Phenylpropyl] ammonium. Mp 112-119 ° C. ,
    Calculated, : C 63.99) ^ ’5.91)
    N 3.73 Found D: C 63.77) Y 6.19;
    N 3.90.
    N-methyl-H- (3 ~ (p-methoxyphenoxy) -3-phenylpropyl} -ammonium maleate. Melting point 128.5-135 ° C.
    Calculated, : C 65.10) H 6.50, '
    N, 3.62.
    Found D: C 64.94) H 6.5 ^)
    N, 3.67.
    Oxalate M, M-dimethyl-I-£ 3- (o-bromophenoxy) -3 “phenylpropyl] -ammonium. Mp 144-146 ° C.
    Calculated D: C 53.79) H 5.23)
    N, 3.30; g, 18.56.
    Found,% ·. C 53.84; H 5.52)
    N, 3.38; ' Wh 18.86.
    N-methyl-M- [3 _ (o-allylphenoxy) -3 ~ phenylpropyl] -ammonium oxalate. Mp 144-147 ° C. (Decomposition).
    Calculated D: C 67.91; H 6.78)
    N, 3.77.
    Found D: C, 67.90; H 6.85;
    • N 3.96.
    N-oxalate, M-dimethyl-M - з 3 ~ (mtrifluoromethylphenoxy) -3-phenylpropyl] -ammonium. Mp 1bZ ~ 1b5 ° C.
    Calculated. D: C 58.11; H 5.36, *
    N 3.39) F 13.79.
    Found D: C, 57.89; H 5.2)
    N 3.41j F 13.691
    Oxalate N t M-dimethyl-M- £ 3 ~ (o-tert-butylphenoxy) -3 “phenylpropyl] -ammonium. T.pp 146-190 cto
    Calculated D: C 68.88) H 7.78;
    N 3Λ9.
    Found D: C 68.56) H 8.04; '
    N, 3.69.
    M-methyl-M- [z _ (p-fluorophenoxy) -3-phenylpropyl] -ammonium oxalate.
    Mp 159-1b1 ° C.
    Calculated D: C 61.88; H 5.77;
    N, 4.01-, F, 5.44.
    Found D: C 61, 66} H 5.90,
    3.72, F 5.70.
    M-methyl-L-£ 3 (o-methoxyphenoxy) -3-phenylpropyl] -ammonium chloride. Mp 105 _ 8 ° C (recrystallized from ethyl acetate).
    Calculated D: C 66.33) H 7.20, ’N4.55, C £ 11.52.
    Found D: C 66.16) H 7.36)
    N, 4.41; CE 11.48.
    M-methyl-H- £ 3 “(o-fluorophenoxy) -3 - phenylpropyl] -ammonium oxalate. Mp 148-150 ° C.
    Calculated D: C 61.88; H 5.77, '
    N 4.01) F 5.44.
    Found D /. C 61.83) H 5.97;
    N, 4.14; F 5.65 N-methyl-I -> 3- (m-methoxyphenoxy) -3-phenylpropi.p] -ammonium oxalate. Mp 140-143 ^ 0.
    Calculated D: C 63.15) H 6.42)
    N, 3.88.
    Found D: C, 62.91 ', Η 6.4θ) N, 4.17. ...
    N, K-dimethyl-Y- [3 ~ (o-ethylphenoxy) -3-phenylpropyl] -ammonium oxalate. Mp 152-154 ° C.,
    Calculated D: C 67.5 ^) H 7.29;
    N 3.75 Found: C 67.33) H 7.05)
    N, 3.98.
    Oxalate N> I-dimethyl-M- £ 3- (o-isopropoxyphenoxy) -3-phenylpropyl} -ammonium. Mp 139 “142 ° C.
    Calculated, : C 68.20) And 7.54) N 3.61.
    Found D: C, 68.50; H 7.82; N 3.85.
    M-methyl-M- 3 (p-chlorophenoxy) -3-phenylpropyl] -ammonium oxalate. Mp 163-165 ° C.
    Calculated, : C 59.1 O ’, H 5.51) N 3.83 * CE 9.69.
    Found, : C 59.33) H 5.58;
    N, 4.07; CE 9.45.
    N-dimethyl-M -> 3 - (p-fluorophenoxy) -3-phenylpropyl] -ammonium maleate. Mp 103 -10 ° C.
    Calculated, : C 64.77) H 6.21)
    N, 3.60.
    Found D: C (A, 79 ί H 6.50 ί N 3.82.
    Oxalate Nf M ~ dimethyl-L- £ 3 · ’(mphenoxy) -3-phenylpropyl} -ammonia. Mp 150-152 ° C.
    Calculated D: C 60.08; H 5.87;
    N 3.69, se 9.33.
    Found D: C, 59.90; H, 6.08;
    N 3.42 ’, CE 9.60.
    Hydrochloride> 1, Y-dimethyl-H- £ 3 _ 10 - (o-fluorophenoxy) -3 “phenylpropyl] -am; on. T. pl. 166-168 ° C (from acetone cyclohexane).
    Calculated D: C 65.911 H 6.831
    N, 4.52; FROM! 11.99; F 6.13. * 5
    Found D: C, 65.78; H, 6.82; .
    N, 4.78; CI 11.70; f 5.99.
    L-methyl-H- £ 3-phenoxy-3 “phenyl-2-methylpropylZ ~ ammonium oxalate.
    Mp 15.81 ° C (from isopropanol). 20 Calculated D: s 66.07; H 6.74
    N 4, About.
    Found D: C * 66.12, H 6.72;
    N, 4.26.
    N-methyl-L-£ 3-phenoxy-3 * 25- phenyl.-1-methylpropyl] -ammonium oxalate.
    Mp. 80-100 ° C with decomposition, recrystallized from ethyl acetate).
    Calculated D: C 66.071 H 6.71 N4.06. thirty
    Found D: C, 65.851; H, 6.45;
    N, 4.20.
    Oxalate dL-d £ - N, L-dimethyl-I -> 3 phenoxy-3-phenyl-1-methylpropyl] ammonium. Mp 113-116 ° C. 35
    Calculated D: C 66.84; H 7.01; N, 3.90.
    Found D: C 67.031 H 7DO, Ν 4.13.
    Oxalate N, N-dimethyl-L-£ 3-pheno-40 si-3-phenyl-2-methylpropylZ-ammonium. Mp .130-134 ° С.
    Calculated D: C, 66.89; H, 7.01; N, 3.90.
    Found D: C, 66.597; H, 7.08; 4S
    N, 3.96.
    I
    Oxalate Ν-Μετπη-Ν- [3 “(m-fluorophenoxy-3 _ phenylpropylZ-ammonium.
    Mp 117-179 * 0. ''
    Calculated D: C 61.871 H 5.77;
    N, 4.0i; F 5.44. . Found D: C, 62.07; H, 6.02;
    N 4.23, 'F 5DZ.
    Oxalate VI, M-dimethyl-I-£ 3- (o-ethoxy 50 siphenoxy) -3 “phenylpropylJ-ammonium. Mp 101-104 ° C.
    Calculated D: C 64.77; H 6.99; N, 3.60.
    Found D: C 65.05 ', H 7.00; ί
    N, 3.88.
    Oxalate (5-c | £ -N, Ν-dimethyl-I-Gz-phenoxy-3-phenyl-1-methylpropylZ ~ ammonium. Mp. 131-133 C.
    *
    Calculated D: C 66.89, H 7.0'1 ’, N 3.90.
    . Found D: C, 66.64; H, 7.00 '; N, 3.77.
    As a result of studying the psychotropic activity of the described compounds, it was found that they block the accumulation of various physiologically active monoamines. This blockade was detected in vitro with radioactive labeled compounds obtained by the proposed method.
    In addition, some of the compounds described exhibit unique selectivity in that they block the accumulation of one monoamine to a much greater extent than the accumulation of the other two.
    权利要求:
    Claims (2)
    [1]
    1.US Patent No. SOF.
    cl. 2b-32b.5, published. 08,10.63.
    [2]
    2. Buhler K., Pearson D. Organic syntheses.4.1. M., World, 1973,
    s, 326-327.
    类似技术:
    公开号 | 公开日 | 专利标题
    SU1005655A3|1983-03-15|Process for producing 3-aryloxy-3-phenyl-propyl amines or their salts
    Johnson et al.1973|Chemistry of sulfoxides and related compounds. XLV. Asymmetric syntheses using optically active oxosulfonium alkylides
    US3225095A|1965-12-21|N-aryl-substituted-propan-|-ones and -ols of arylaminoalkanols and salts thereof
    IE930475A1|1993-12-29|Process for the preparation of¹N-methyl-3-phenyl-3-[4-|phenoxy]propylamine¹and acid addition salts thereof
    DK147068B|1984-04-02|ANALOGY PROCEDURE FOR PREPARING 1-NAPHTHYLMETHYL-CINNAMYL-AMINE DERIVATIVES
    FR2582309A1|1986-11-28|NOVEL DERIVATIVES OF MORPHINANE AND MORPHINE, THEIR PREPARATION, THEIR APPLICATION AS MEDICAMENTS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
    TW514634B|2002-12-21|Process to make chiral compounds
    EP1274685B1|2006-07-12|A pyridine-n-oxide derivative, and process for its transformation into pharmaceutically effective compounds
    US2599001A|1952-06-03|Nu, nu-disubstituted-beta-haloalkylamines
    JPH07116116B2|1995-12-13|Process for producing 3-aminoacrylic acid ester
    US4645778A|1987-02-24|2-|-3-isobutoxy-n-substituted-phenyl-n-benzyl-propylamines, their preparation and pharmaceutical use
    US2571755A|1951-10-16|Preparation of threonine and intermediates therefor
    HU199798B|1990-03-28|Process for producing 2-substituted-5-methyl-pyridine derivatives
    Anderson et al.1978|A useful synthesis of 3-oxodihydroisoindoles
    JP2651028B2|1997-09-10|Hydroxylamine derivative
    US2671798A|1954-03-09|2, 2-diphenyl-3-methyl-4-chlorobutyronitrile and processes for preparing the same
    JPWO2008093881A1|2010-05-20|Synthesis of nitroxyl radical
    BE739678A|1970-04-01|1 subst phenyl 2 amino ethanols useful as beta - adrenergic agents peripheral vasodilators and hypo-
    US3360562A|1967-12-26|2-tertiaryaminomethyl-n-acylanilines
    SU434654A3|1974-06-30|METHOD OF OBTAINING TROPAN-3-OLA DERIVATIVES
    Stanciuc et al.1993|Reaction of pyrylium salts with nucleophiles. 23: Triarylethene derivatives containing an oxyalkyleneamino or oxyalkylene-N-pyridinium side chain
    US2921080A|1960-01-12|Process for making 5-cyano-2-allyl-pyrrolidines and products therefrom
    SU457211A3|1975-01-15|The method of obtaining derivatives of 1-phenoxy-3-aminopropan-2-ol
    US2763687A|1956-09-18|Fluorene derivatives
    US3549703A|1970-12-22|Process for making n-|-n-methylhydrocarbon sulfonamides
    同族专利:
    公开号 | 公开日
    JPS50101333A|1975-08-11|
    YU37307B|1984-08-31|
    RO70660A|1983-09-26|
    YU121481A|1983-04-27|
    RO69763A|1982-02-26|
    DK140430B|1979-08-27|
    NL930108I1|1993-10-18|
    GB1493961A|1977-12-07|
    AR205577A1|1976-05-14|
    FR2257288A1|1975-08-08|
    FR2257288B1|1978-07-21|
    NL930108I2|1994-08-16|
    NL7500186A|1975-07-14|
    BG26192A3|1979-02-15|
    BE824255A|1975-07-09|
    DE2500110A1|1975-07-17|
    YU121581A|1983-04-27|
    DK688974A|1975-09-01|
    BG23212A3|1977-07-12|
    NL181654C|1987-10-01|
    SE7500215L|1975-07-11|
    RO70660B|1983-08-30|
    CS189680B2|1979-04-30|
    ES433720A1|1976-12-01|
    PH11652A|1978-05-08|
    SE412906B|1980-03-24|
    ZA7532B|1976-08-25|
    ATA10275A|1976-08-15|
    DD118613A5|1976-03-12|
    CH609675A5|1979-03-15|
    YU36915B|1984-08-31|
    IE40346L|1975-07-10|
    DK140430C|1980-01-21|
    DE2500110C2|1987-06-11|
    IE40346B1|1979-05-09|
    AR205578A1|1976-05-14|
    YU3275A|1982-06-18|
    YU37308B|1984-08-31|
    BG60761B2|1996-02-29|
    US4314081A|1982-02-02|
    AU7683674A|1976-06-24|
    NL181654B|1987-05-04|
    CA1051034A|1979-03-20|
    JPS5939418B2|1984-09-22|
    AT336000B|1977-04-12|
    AR205633A1|1976-05-21|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    US2683742A|1951-02-23|1954-07-13|Searle & Co|Nu, nu-disubstituted omega-arylmethoxy-omega-arylalkylamine derivatives|
    ES251290A1|1958-08-21|1960-04-01|Parke Davis & Co|1- pyrrolidine|
    US3132179A|1959-08-27|1964-05-05|Sterling Drug Inc|Ethers of alpha-hydroxymethyl-beta-monocarbocyclic aryl ethyl amines and their preparation|
    US3253040A|1962-12-10|1966-05-24|Union Carbide Corp|Process for the production of primary 3-hydrocarbyloxypropylamines|US4584404A|1974-01-10|1986-04-22|Eli Lilly And Company|Substituted phenoxyphenylproply dimethylamines|
    US4626549A|1974-01-10|1986-12-02|Eli Lilly And Company|Treatment of obesity with aryloxyphenylpropylamines|
    JPS5283811A|1976-01-01|1977-07-13|Lilly Co Eli|Aryloxy phenyl propylamines and their salts|
    GB1570613A|1976-10-27|1980-07-02|Akzo Nv|Biologically active tricyclic compounds and pharmaceutical compositions containing same|
    IL56369A|1978-01-20|1984-05-31|Erba Farmitalia|Alpha-phenoxybenzyl propanolamine derivatives,their preparation and pharmaceutical compositions comprising them|
    FR2432500B1|1978-02-24|1981-01-16|Roussel Uclaf|
    FR2455571B2|1979-02-15|1983-10-28|Roussel Uclaf|
    DE3017812A1|1980-05-09|1981-11-12|Merck Patent Gmbh, 6100 Darmstadt|CYCLOPROPANE DERIVATIVES, PHARMACEUTICAL PREPARATIONS CONTAINING THEM AND METHOD FOR THE PRODUCTION THEREOF|
    US4430319A|1982-05-21|1984-02-07|State University Of New York|Radioactive iodine labeled phenolic amines|
    US4692469A|1982-09-07|1987-09-08|Ciba-Geigy Corporation|Propylamine derivatives|
    US4824868A|1982-09-07|1989-04-25|Ciba-Geigy Corporation|Propylamine derivatives useful for the treatment of dementia|
    US4590213A|1983-04-08|1986-05-20|Eli Lilly And Company|Anti-anxiety method|
    HU207282B|1984-05-31|1993-03-29|Chinoin Gyogyszer Es Vegyeszet|Process for producing phenyl-alkyl-amine derivatives and pharmaceutical compositions containing them|
    US4683235A|1985-02-25|1987-07-28|Eli Lilly And Company|Analgesic method|
    US4594358A|1985-02-25|1986-06-10|Eli Lilly And Company|Analgesic method|
    US4777291A|1985-02-27|1988-10-11|Eli Lilly And Company|Racemization process|
    US4956388A|1986-12-22|1990-09-11|Eli Lilly And Company|3-aryloxy-3-substituted propanamines|
    US5135947A|1987-04-09|1992-08-04|Eli Lilly And Company|1-phenyl-3-naphthalenyloxypropanamines and their use as selective serotonin reuptake inhibitors|
    ZA885824B|1987-08-14|1989-04-26|Merrell Dow Pharma|Novel antidepressants|
    US5149714A|1987-08-14|1992-09-22|Merrell Dow Pharmaceuticals Inc.|Antidepressants|
    US4971998A|1987-10-22|1990-11-20|Massachusetts Institute Of Technology|Methods for treating the premenstrual or late luteal phase syndrome|
    US5223540A|1987-10-22|1993-06-29|Massachusetts Institute Of Technology|Method for treating the premenstrual or late luteal phase syndrome|
    US4876282A|1987-11-25|1989-10-24|Eli Lilly And Company|1-Phenylalkylamines as selective serotonin uptake inhibitors|
    US4996235A|1987-11-25|1991-02-26|Eli Lilly And Company|3,4-diphenylbutanamines|
    ZA892517B|1988-04-08|1990-12-28|Lilly Co Eli|Propanamine derivatives|
    US5238959A|1988-04-08|1993-08-24|Eli Lilly And Company|3-phenyloxy-3-phenyl propanamines|
    US5250571A|1988-11-14|1993-10-05|Eli Lilly And Company|-norfluoxetine in method of inhibiting serotonin uptake|
    US4902710A|1988-12-14|1990-02-20|Eli Lilly And Company|Serotonin and norepinephrine uptake inhibitors|
    US5114976A|1989-01-06|1992-05-19|Norden Michael J|Method for treating certain psychiatric disorders and certain psychiatric symptoms|
    IT1228209B|1989-01-10|1991-06-05|Grato Magnone|PROCEDURE FOR THE PREPARATION OF FLUOXETINE HYDROCHLORIDE.|
    US5166437A|1989-03-03|1992-11-24|Orion-Yhtyma Oy|Process for the preparation of fluoxetine|
    FI81083C|1989-03-03|1990-09-10|Orion Yhtymae Oy|ETT FOERBAETTRAT FOERFARANDE FOER FRAMSTAELLNING AV N-METHYL-3--3-PHENYLPROPYLAMINE HYDROCHLORIDE.|
    DK258389D0|1989-05-26|1989-05-26|Ferrosan As|ARYLOXYPHENYL PROPYLAMINES, THEIR PREPARATION AND USE|
    JPH0375680U|1989-11-21|1991-07-30|
    US5021426A|1990-02-26|1991-06-04|Merck & Co., Inc.|Method of traeting malaria with cyproheptadine derivatives|
    US5356934A|1990-03-29|1994-10-18|Eli Lilly And Company|Selected serotonin subtype receptor agonist to treat sleep apnea|
    US5250572A|1990-03-29|1993-10-05|Eli Lilly And Company|-norfluoxetine in method for occupying serotonin IC receptors|
    US5589511A|1990-08-13|1996-12-31|Sepracor Inc.|Method for treating migraine headaches using optically pure S fluoxetine|
    US5708035A|1991-02-04|1998-01-13|Sepracor Inc.|Methods of use and compositions of R fluoxetine|
    PH30083A|1991-02-25|1996-12-27|Lilly Co Eli|Treatment of lower urinary tract disorders|
    US5136078A|1991-02-26|1992-08-04|Eli Lilly And Company|Synthesis of b-cyanohydrins|
    US5136079A|1991-02-26|1992-08-04|Eli Lilly And Company|Regioselective synthesis|
    US5320825A|1991-05-01|1994-06-14|Trustees Of The University Of Pennsylvania|Serotonin reuptake inhibitors for S.P.E.C.T. imaging|
    WO1993000811A1|1991-07-01|1993-01-21|The General Hospital Corporation|Invertebrate phenylethanolamine transporter and the use thereof|
    IL99316A|1991-08-27|1995-03-15|Teva Pharma|Production of fluoxetine and new intermediates|
    US5202319A|1991-09-23|1993-04-13|Hoechst-Roussel Pharmaceuticals Inc.|Substituted 3-amino-2,3,4,5-tetrahydro-1-aryloxy-3-benzazepines|
    US5281624A|1991-09-27|1994-01-25|Eli Lilly And Company|N-alkyl-3-phenyl-3- propylamines and pharmaceutical use thereof|
    DK0537915T3|1991-09-27|1995-11-27|Lilly Co Eli|N-alkyl-3-phenyl-3-propylamines as inhibitors of epinephrine|
    HU9202128D0|1992-06-26|1992-10-28|Richter Gedeon Vegyeszet|Method for producing n-methyl--phenooxi-)-amine|
    EP0576766A1|1992-06-29|1994-01-05|Novo Nordisk A/S|Propanolamine derivatives, their preparation and use|
    US6017965A|1993-02-08|2000-01-25|Nps Pharmaceuticals, Inc.|Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases|
    US7087765B2|1995-06-07|2006-08-08|Nps Pharmaceuticals, Inc.|Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases|
    TW344661B|1993-11-24|1998-11-11|Lilly Co Eli|Pharmaceutical composition for treatment of incontinence|
    CA2134038C|1994-06-16|1997-06-03|David Taiwai Wong|Potentiation of drug response|
    ES2082723B1|1994-07-20|1996-10-01|Lilly Sa|PHARMACEUTICAL FORMULATION OF FLUOXETINE IN A DISPERSIBLE FORM.|
    EP0714663A3|1994-11-28|1997-01-15|Lilly Co Eli|Potentiation of drug response by a serotonin 1A receptor antagonist|
    US5576321A|1995-01-17|1996-11-19|Eli Lilly And Company|Compounds having effects on serotonin-related systems|
    US5741789A|1995-01-17|1998-04-21|Eli Lilly And Company|Compounds having effects on serotonin-related systems|
    ES2101650B1|1995-06-29|1998-01-16|Lilly Sa|PROCEDURE FOR THE PREPARATION OF N-METHYL-3-PHENYL-3-PROPYLAMINE.|
    US6548084B2|1995-07-20|2003-04-15|Smithkline Beecham Plc|Controlled release compositions|
    ES2101654B1|1995-07-24|1998-01-16|Lilly Sa|N-METHYL-3-PHENYL-3-PROPYLAMINE PREPARATION PROCEDURE.|
    ES2101655B1|1995-07-28|1998-01-16|Lilly Sa|N-METHYL-3-PHENYL-3-PROPYLAMINE PREPARATION PROCEDURE.|
    ES2103680B1|1995-08-03|1998-04-01|Lilly Sa|PROCEDURE FOR THE PREPARATION OF N-METHYL-3-PHENYL-3-PROPYLAMINE.|
    DK0759299T3|1995-08-16|2000-08-07|Lilly Co Eli|Potentiation of serotonin response|
    ES2103681B1|1995-09-19|1998-04-01|Lilly Sa|PREPARATION PROCEDURE OF N-METHYL-3-PHENYL -PROPYLAMINE.|
    IT1283141B1|1996-07-11|1998-04-07|Laporte Organics Francis S P A|PROCEDURE FOR THE PREPARATION OF N-METHYL-3--3-PHENYLPROPILAMINE AND ITS|
    US6512010B1|1996-07-15|2003-01-28|Alza Corporation|Formulations for the administration of fluoxetine|
    US6203817B1|1997-02-19|2001-03-20|Alza Corporation|Reduction of skin reactions caused by transdermal drug delivery|
    US5830500A|1996-07-22|1998-11-03|Pentech Pharmaceuticals, Inc.|Low dose fluoxetine tablet|
    ZA977967B|1996-09-23|1999-03-04|Lilly Co Eli|Combination therapy for treatment of psychoses|
    US5910319A|1997-05-29|1999-06-08|Eli Lilly And Company|Fluoxetine enteric pellets and methods for their preparation and use|
    AT289816T|1997-11-14|2005-03-15|Akzo Nobel Nv|USE OF MIRTAZAPINE FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF SLEEP APNOES|
    US5936124A|1998-06-22|1999-08-10|Sepacor Inc.|Fluoxetine process from benzoylpropionic acid|
    US6025517A|1998-08-03|2000-02-15|Sepracor Inc.|Fluoxetine process from benzoylacetonitrile|
    WO2000041684A1|1999-01-13|2000-07-20|Warner-Lambert Company|A pharmaceutical combination for the treatment of depression|
    JP4625637B2|2002-02-22|2011-02-02|シャイアエルエルシー|Active substance delivery system and method for protecting and administering an active substance|
    FR2791345B1|1999-03-26|2001-05-04|Adir|NOVEL BENZO [3,4] CYCLOBUTA [1,2-C] PYRROLE DERIVATIVES, THEIR PREPARATION PROCESS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM|
    AU3219800A|1999-03-29|2000-10-16|Eli Lilly And Company|Stereospecific method for preparing tomoxetine and intermediates thereof|
    EP1225881B1|1999-09-03|2006-02-22|APBI Holdings, LLC|The use of dapoxetine, a rapid-onset selective serotonin reuptake inhibitor, for treating sexual dysfunction|
    EP1242362A4|1999-12-17|2003-07-09|Ranbaxy Lab Ltd|Process for the preparation of fluoxetine hydrochloride|
    GB0004153D0|2000-02-23|2000-04-12|Astrazeneca Uk Ltd|Novel use|
    GB0004152D0|2000-02-23|2000-04-12|Astrazeneca Uk Ltd|Novel compounds|
    GB0004151D0|2000-02-23|2000-04-12|Astrazeneca Uk Ltd|Novel use|
    GB0004149D0|2000-02-23|2000-04-12|Astrazeneca Uk Ltd|Novel compounds|
    US6273260B1|2000-03-08|2001-08-14|Eli Lilly And Company|Pharmaceutical packaging system|
    GB2357762B|2000-03-13|2002-01-30|Lundbeck & Co As H|Crystalline base of citalopram|
    AU2001257022B2|2000-04-13|2005-02-03|Mayo Foundation For Medical Education And Research|Abeta 42 lowering agents|
    US20040034106A1|2001-11-06|2004-02-19|Read Holly Ann|Treatment of anxiety disorders|
    IL139975D0|2000-11-29|2002-02-10|Univ Ramot|Anti proliferative drugs|
    US20050013853A1|2000-11-29|2005-01-20|Irit Gil-Ad|Anti-proliferative drugs|
    US6310251B1|2001-01-31|2001-10-30|Grayson Walker Stowell|Form a of fluoxetine hydrochloride|
    US6313350B1|2001-01-31|2001-11-06|Grayson Walker Stowell|Form a of fluoxetine hydrochloride|
    US6258853B1|2001-01-31|2001-07-10|Grayson Walker Stowell|Form a of fluoxetine hydrochloride|
    US6310250B1|2001-01-31|2001-10-30|Grayson Walker Stowell|Form A of fluoxetine hydrochloride|
    US6316672B1|2001-01-31|2001-11-13|Grayson Walker Stowell|Form a of fluoxetine hydrochloride|
    AT414238B|2001-03-06|2006-10-15|Lilly Co Eli|NEW HYDROXYLATED 3-PHENOXY-3-PHENYL-1-AMINOPROPAN AND PHARMACEUTICAL FORMULATION CONTAINING SUCH AMINOPROPANE|
    US6645946B1|2001-03-27|2003-11-11|Pro-Pharmaceuticals, Inc.|Delivery of a therapeutic agent in a formulation for reduced toxicity|
    AR035700A1|2001-05-08|2004-06-23|Astrazeneca Ab|DERIVATIVES OF ARILHETEROALQUILAMINA, PHARMACEUTICAL COMPOSITION, USES OF THESE DERIVATIVES FOR THE MANUFACTURE OF MEDICINES, TREATMENT METHODS, AND PROCESS FOR THE PREPARATION OF THESE DERIVATIVES|
    US7034059B2|2001-07-02|2006-04-25|Sepracor Inc.|Methods of using norfluoxetine|
    AU2002322720B2|2001-07-25|2008-11-13|Raptor Pharmaceutical Inc.|Compositions and methods for modulating blood-brain barrier transport|
    CA2452347A1|2001-07-31|2003-02-13|Pharmacia & Upjohn Company|Treatment of chronic pain with 3-aryloxy-3-phenylpropanamines|
    SE0102640D0|2001-07-31|2001-07-31|Astrazeneca Ab|Novel compounds|
    SE0102641D0|2001-07-31|2001-07-31|Astrazeneca Ab|Novel compounds|
    US20040170688A1|2001-08-06|2004-09-02|Deshmukh Abhijit Mukund|Enteric formulation of fluoxetin|
    CA2457385A1|2001-08-06|2003-02-20|Dr. Reddy's Laboratories Ltd.|Improved enteric formulation of fluoxetin|
    US6630454B2|2001-09-10|2003-10-07|Ramot At Tel-Aviv University Ltd.|Method and pharmaceutical composition for the treatment of cancer|
    NZ532033A|2001-10-12|2006-11-30|Azevan Pharmaceuticals Inc|2-alkanedioic acid derivatives as vasopressin V1a receptor antagonists|
    JP2005515199A|2001-11-30|2005-05-26|イーライ・リリー・アンド・カンパニー|Use of norepinephrine reuptake inhibitors for the treatment of tic disorders|
    US20050009925A1|2001-12-11|2005-01-13|Bymaster Franklin Porter|Use of norepinephrine reuptake inhibitors for the treatment of cognitive failure|
    US7326733B2|2002-05-31|2008-02-05|The Forsyth Institute|Methods for increasing bone density|
    JP2004077714A|2002-08-15|2004-03-11|Fuji Xerox Co Ltd|Optical scanner|
    SE0203304D0|2002-11-07|2002-11-07|Astrazeneca Ab|Novel Coumpounds|
    US6846957B2|2002-11-22|2005-01-25|Board Of Regents, The University Of Texas System|Synthesis of 3-aminomethyl-1-propanol, a fluoxetine precursor|
    US20040235925A1|2002-12-17|2004-11-25|Pharmacia Corporation|Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of duloxetine, venlafaxine or atomoxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof|
    EP1603548A4|2003-02-05|2007-10-10|Myriad Genetics Inc|Method and composition for treating neurodegenerative disorders|
    CA2522666A1|2003-04-18|2004-10-28|Pharmacia & Upjohn Company Llc|Combination therapies for chronic obstructive pulmonary disease |
    KR20060021870A|2003-05-30|2006-03-08|랜박시 래보러터리스 리미티드|Substituted pyrrole derivatives and their use as hmg-co inhibitors|
    CA2532207A1|2003-07-11|2005-07-21|Myriad Genetics, Inc.|Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease|
    WO2005011583A2|2003-07-28|2005-02-10|Leslie Joe Dunaway|Treatment of allergic rhinitis and asthma|
    WO2005025675A1|2003-09-12|2005-03-24|Pfizer Limited|Combinations comprising alpha-2-delta ligands and serotonin / noradrenaline re-uptake inhibitors|
    AT420881T|2003-09-17|2009-01-15|Janssen Pharmaceutica Nv|CONDENSED HETEROCYCLIC COMPOUNDS AS MODULATORS OF THE SEROTONIN RECEPTOR|
    WO2005051919A1|2003-11-26|2005-06-09|Pfizer Products Inc.|Aminopyrazole derivatives as gsk-3 inhibitors|
    AU2004305563C1|2003-12-11|2011-07-07|Sunovion Pharmaceuticals Inc.|Combination of a sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression|
    ES2390879T3|2003-12-31|2012-11-19|Actavis Group Ptc Ehf.|Atomoxetine formulations|
    US7893261B2|2004-03-26|2011-02-22|Baylor University|Serotonin reuptake inhibitors|
    US20070293538A1|2004-04-13|2007-12-20|Myriad Genetics, Incorporated|Pharmaceutical Composition And Methods For Treating Neurodegenerative Disorders|
    EP1737473A4|2004-04-19|2009-08-26|Noven Therapeutics Llc|Lithium combinations, and uses related thereto|
    WO2005108683A1|2004-04-29|2005-11-17|Keystone Retaining Wall Systems, Inc.|Veneers for walls, retaining walls and the like|
    WO2006020852A2|2004-08-11|2006-02-23|Myriad Genetics, Inc.|Pharmaceutical composition and method for treating neurodegenerative disorders|
    CA2618985A1|2004-08-11|2006-02-23|Myriad Genetics, Inc.|Pharmaceutical composition and method for treating neurodegenerative disorders|
    WO2006020850A2|2004-08-11|2006-02-23|Myriad Genetics, Inc.|Pharmaceutical composition and method for treating neurodegenerative disorders|
    US20080004470A1|2004-09-27|2008-01-03|Mathad Vijayavitthal T|Synthesis of Atomoxetine Hydrochloride|
    EP1730132A2|2004-12-23|2006-12-13|Teva Pharmaceutical Industries Ltd|Process for preparing pharmaceutically acceptable salts of duloxetine and intermediates thereof|
    US7399871B2|2005-03-08|2008-07-15|Teva Pharmaceutical Industries Ltd.|Crystal forms of --N,N-dimethyl-3--3-propanamine oxalate and the preparation thereof|
    WO2006099457A1|2005-03-14|2006-09-21|Teva Pharmaceutical Industries Ltd.|-n,n-dimethyl-3--3- propanamine-di-p-toluoyl-l-tartarate and methods of preparation thereof|
    WO2006102308A2|2005-03-22|2006-09-28|Azevan Pharmaceuticals, Inc.|Beta-lactamyl vasopressin v1b antagonists|
    EP1871356A1|2005-04-22|2008-01-02|Wyeth a Corporation of the State of Delaware|Dihydrobenzofuran derivatives and uses thereof|
    MX2007012883A|2005-04-22|2007-12-10|Wyeth Corp|Dihydrobenzofuran derivatives and uses thereof.|
    CA2605554A1|2005-04-22|2006-11-02|Wyeth|Benzofuranyl alkanamine derivatives and uses thereof as 5-ht2c agonists|
    WO2006116218A1|2005-04-22|2006-11-02|Wyeth|Crystal forms of {[-7--5-fluoro-2,3-dihydro-1-benzofuran-2-yl]methyl}amine hydrochloride|
    JP2008539047A|2005-04-28|2008-11-13|プロテウスバイオメディカルインコーポレイテッド|Pharma Informatics System|
    US20070015138A1|2005-07-08|2007-01-18|Braincells, Inc.|Methods for identifying agents and conditions that modulate neurogenesis|
    US7485754B2|2005-07-08|2009-02-03|Apotex Pharmachem Inc.|Efficient method for preparing 3-aryloxy-3-arylpropylamines and their optical stereoisomers|
    US20070015832A1|2005-07-14|2007-01-18|Myriad Genetics, Incorporated|Methods of treating overactive bladder and urinary incontinence|
    TR201907381T4|2005-07-19|2019-06-21|Azevan Pharmaceuticals Inc|Beta-lactamyl phenylalanine, cysteine and serine vasopressin antagonist.|
    JP2009502807A|2005-07-22|2009-01-29|ミリアドジェネティクス，インコーポレイテッド|Formulations and dosage forms with high drug content|
    US7598255B2|2005-08-04|2009-10-06|Janssen Pharmaceutica Nv|Pyrimidine compounds as serotonin receptor modulators|
    EP2258357A3|2005-08-26|2011-04-06|Braincells, Inc.|Neurogenesis with acetylcholinesterase inhibitor|
    WO2008036682A2|2006-09-18|2008-03-27|Raptor Pharmaceutical Inc.|Treatment of liver disorders by administration of receptor-associated protein -conjugates|
    EP1838692A2|2005-09-22|2007-10-03|Teva Pharmaceutical Industries Ltd|Dnt-maleate and methods of preparation thereof|
    US20080207923A1|2005-09-22|2008-08-28|Santiago Ini|Pure DNT-maleate and methods of preparation thereof|
    WO2007134136A2|2006-05-09|2007-11-22|Braincells, Inc.|Neurogenesis by modulating angiotensin|
    CA2625153A1|2005-10-21|2007-04-26|Braincells, Inc.|Modulation of neurogenesis by pde inhibition|
    EP1942879A1|2005-10-31|2008-07-16|Braincells, Inc.|Gaba receptor mediated modulation of neurogenesis|
    EP1948599A1|2005-11-08|2008-07-30|Ranbaxy Laboratories Limited|Process for -7-[2--5-isopropyl-3-phenyl-4- [ carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt|
    CN1304360C|2005-12-12|2007-03-14|天津大学|Preparation method of N,N-dimethyl-3-hydroxy-3-aryl propyl amine|
    MX2007011611A|2006-01-23|2007-10-18|Teva Pharma|Dnt-fumarate and methods of preparation thereof.|
    WO2007104035A1|2006-03-08|2007-09-13|Braincells, Inc.|Modulation of neurogenesis by nootropic agents|
    US20100216734A1|2006-03-08|2010-08-26|Braincells, Inc.|Modulation of neurogenesis by nootropic agents|
    US20070238716A1|2006-03-14|2007-10-11|Murthy Ayanampudi S R|Statin stabilizing dosage formulations|
    AR060087A1|2006-03-24|2008-05-21|Wyeth Corp|NEW THERAPEUTIC COMBINATIONS FOR THE TREATMENT OF DEPRESSION|
    US20100009983A1|2006-05-09|2010-01-14|Braincells, Inc.|5 ht receptor mediated neurogenesis|
    EP2026813A2|2006-05-09|2009-02-25|Braincells, Inc.|5 ht receptor mediated neurogenesis|
    US7858611B2|2006-05-09|2010-12-28|Braincells Inc.|Neurogenesis by modulating angiotensin|
    WO2007139984A2|2006-05-23|2007-12-06|Teva Pharmaceutical Industries Ltd.|Duloxetine hcl polymorphs|
    US20080033045A1|2006-07-07|2008-02-07|Myriad Genetics, Incorporated|Treatment of psychiatric disorders|
    TW200811101A|2006-07-14|2008-03-01|Ranbaxy Lab Ltd|Polymorphic forms of an HMG-CoA reductase inhibitor and uses thereof|
    TW200817003A|2006-07-31|2008-04-16|Sanofi Aventis|Pharmaceutical composition comprising, in combination, saredutant and a selective serotonin peuptake inhibitor or a serotonin/norepinephrine reuptake inhibitor|
    WO2008026227A2|2006-08-28|2008-03-06|Matrix Laboratories Ltd|A process for the preparation of atomoxetine hydrochloride|
    US7998971B2|2006-09-08|2011-08-16|Braincells Inc.|Combinations containing a 4-acylaminopyridine derivative|
    US20100016274A1|2006-09-14|2010-01-21|Koppel Gary A|Beta-lactam cannabinoid receptor modulators|
    CA2663347A1|2006-09-19|2008-03-27|Braincells, Inc.|Ppar mediated modulation of neurogenesis|
    US20100184806A1|2006-09-19|2010-07-22|Braincells, Inc.|Modulation of neurogenesis by ppar agents|
    ITMI20061987A1|2006-10-16|2008-04-17|Archimica Srl|PROCESS FOR THE SYNTHESIS OF ARYLOSSIPROPYLAMINES AND HETERARYLOSOSIPROPYLAMINES.|
    WO2008062473A1|2006-10-31|2008-05-29|Cadila Healthcare Limited|Process for preparing atomoxetine hydrochloride|
    FR2910319B1|2006-12-20|2011-06-03|Substipharm Dev|DISPERSIBLE PHARMACEUTICAL FORMULATIONS CONTAINING FLUOXETINE|
    WO2008083204A2|2006-12-28|2008-07-10|Braincells, Inc.|Modulation of neurogenesis by melatoninergic ligands|
    WO2008086483A2|2007-01-11|2008-07-17|Braincells, Inc.|Modulation of neurogenesis with use of modafinil|
    FR2912057B1|2007-02-07|2009-04-17|Sanofi Aventis Sa|PHARMACEUTICAL COMPOSITION COMPRISING SAREDUTANT AND A SELECTIVE SEROTONIN RECAPTURE INHIBITOR OR SEROTONIN / NOREPINEPHRINE RECAPTURE INHIBITOR|
    WO2008122019A1|2007-04-02|2008-10-09|Cypress Biosciences, Inc.|Improving the tolerability of both mirtazapine and reboxetine by using them in combination|
    EP3524248A1|2007-06-21|2019-08-14|VeroScience LLC|Method of treating metabolic disorders and depression with dopamine receptor agonists|
    WO2009141833A2|2008-04-17|2009-11-26|Ind-Swift Laboratories Limited|An improved process for synthesizing highly pure atomoxetine|
    WO2009128058A1|2008-04-18|2009-10-22|UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN et al|Psycho-pharmaceuticals|
    CN104208718B|2009-02-20|2017-12-29|2-Bbb医疗股份有限公司|drug delivery system based on glutathione|
    US20100216805A1|2009-02-25|2010-08-26|Braincells, Inc.|Modulation of neurogenesis using d-cycloserine combinations|
    WO2011027359A2|2009-07-30|2011-03-10|Matrix Laboratories Ltd|Novel process for the preparation of 4-hydroxy atomoxetine|
    EP2348120B1|2009-12-30|2014-06-11|Universität Wien|Enzymatic reduction of 1-phenylpropanone and derivatives thereof|
    RU2623209C9|2010-07-01|2018-01-22|Азеван Фармасьютикалз, Инк.|Method for ptsd treatment|
    WO2012020418A1|2010-08-12|2012-02-16|Matrix Laboratories Ltd|Novel polymorphs of 4-hydroxy atomoxetine hydrochloride|
    US20120077778A1|2010-09-29|2012-03-29|Andrea Bourdelais|Ladder-Frame Polyether Conjugates|
    WO2012123922A1|2011-03-17|2012-09-20|Lupin Limited|Controlled release pharmaceutical compositions of selective serotonin reuptake inhibitor|
    EA201590047A1|2012-07-31|2015-09-30|Сановел Хайван Саглиги Юрюнлери Санайи Ве Тиджарет А.С.|APPLICATION OF FLUOXETHINE TO INCREASE MEAT AND MILK PRODUCTIVITY|
    WO2014021801A1|2012-07-31|2014-02-06|Sanovel Hayvan Sagligi Ürünleri Sanayi Ve Ticaret A.S.|Use of fluoxetine in animals|
    WO2014046544A1|2012-09-21|2014-03-27|Aapa B.V.|Substituted 3-heteroaryloxy-3-aryl-propylamines as serotonin transporter and serotonin ht2c receptor modulators|
    WO2015148962A1|2014-03-28|2015-10-01|Azevan Pharmaceuticals, Inc.|Compositions and methods for treating neurodegenerative diseases|
    CN105777706B|2014-12-25|2019-08-23|江苏恩华药业股份有限公司|A kind of 3- [-oxygroup] -3- arylprop aminated compounds and its application|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    US05/432,379|US4314081A|1974-01-10|1974-01-10|Arloxyphenylpropylamines|
    KR1019750000261A|KR800001009B1|1975-01-09|1975-01-09|Process for the preparation of aryloxy phenyl-propylamines|
    [返回顶部]